Zorifertinib

Zorifertinib
Clinical data
Other names	AZD3759
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name [4-(3-Chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2R)-2,4-dimethylpiperazine-1-carboxylate;
CAS Number	1626387-80-1;
PubChem CID	78209992;
IUPHAR/BPS	10456;
DrugBank	DB14795;
ChemSpider	38772332;
UNII	67SX9H68W2;
ChEMBL	ChEMBL3623290;
Chemical and physical data
Formula	C22H23ClFN5O3
Molar mass	459.91 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN(CCN1C(=O)OC2=C(C=C3C(=C2)C(=NC=N3)NC4=C(C(=CC=C4)Cl)F)OC)C;
	InChI InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1; Key:MXDSJQHFFDGFDK-CYBMUJFWSA-N;

Zorifertinib (AZD3759) is a drug for the treatment of cancer.^[1] In China, it was approved in 2024 for locally advanced or metastatic non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations and central nervous system (CNS) metastases.^[2]

References

↑ Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, et al. (January 2025). "First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial". Med. 6 (1) 100513. doi:10.1016/j.medj.2024.09.002. PMID 39389055.
↑ "Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases". November 20, 2024.

[1] Zhou Q, Yu Y, Xing L, Cheng Y, Wang Y, Pan Y, et al. (January 2025). "First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial". Med. 6 (1) 100513. doi:10.1016/j.medj.2024.09.002. PMID 39389055.

[2] "Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases". November 20, 2024.

[1]

[2]